1. For Gilead, its coronavirus treatment is icing on the cake— FDA considering virtual advisory panels but delays GSK, Intercept meetings — Sanofi in COVID-19 mRNA vaccine deal with Translate Bio — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

How CMOs can help reduce your manufacturing risk

Discussion in 'Pharma Contract Manufacturing - General Discussion' started by anonymous, Mar 8, 2012 at 3:57 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This new white paper is hosted at Pharmaceutical Technology. Contract manufacturing organizations (CMOs) exist in an environment of continuous improvement and evolving quality standards.

    http://www.pharmtech.com/pharmtech/...cturing/ArticleStandard/Article/detail/758711

    By scientifically affirming every decision and by embracing integral approaches to quality, CMOs can reduce regulatory risk and become a leader in developing best practices meeting current Good Manufacturing Practices (cGMPs).